TA664 for liraglutide 3.0 mg) recommend considering GLP-1 agonists for adults with a BMI of 35 kg/m or more (or 32.5 kg/m or more for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds), or a BMI of 30-34.9 kg/m with at least one weight-related comorbidity
Archived from the original on 5 June 2021
Nat Prod Rep
In return, the growth hormones have influenced the physiological and molecular endpoints related to skeletal muscle development, lipid metabolism, age-associated biological processes, and metabolic regulation in research models
Alternative and non-mutually exclusive mechanisms may involve favorable effects on basal energy expenditure [57] or on the choice of less energy-rich foods consumed in free-living conditions [58], although these latter hypotheses remain to be validated in clinical studies
"Metformin monotherapy for adults with type 2 diabetes mellitus"